Brunswick declared a quarterly dividend on its common stock of $0.40 per share, an increase of 9.6% to the current dividend. The dividend will be payable on March 15, 2023, to shareholders of record at the close of business on February 27, 2023.
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed In Phase 1 Clinical Trial Of Novel Gene-Edited Cell Replacement Therapy For Treatment Of Type 1 Diabetes (T1D)
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing
